alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7814 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7814

To amend the Internal Revenue Code of 1986 to exclude from gross income 
certain federally subsidized loan repayments for dental school faculty.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 22, 2024

Mr. Van Drew (for himself, Ms. Clarke of New York, Mr. Simpson, and Mr. 
    Babin) introduced the following bill; which was referred to the 
Committee on Ways and Means, and in addition to the Committee on Energy 
    and Commerce, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to exclude from gross income 
certain federally subsidized loan repayments for dental school faculty.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Dental Loan Repayment Assistance Act 
of 2024''.

SEC. 2. EXCLUSION OF CERTAIN FEDERALLY SUBSIDIZED LOAN REPAYMENTS FOR 
              DENTAL SCHOOL FACULTY.

    (a) In General.--Section 108(f)(4) of the Internal Revenue Code of 
1986 is amended--
            (1) in the heading, by striking ``Payments under national 
        health service corps loan repayment program and certain state 
        loan repayment programs'' and inserting ``Certain federal and 
        state loan repayment programs'', and
            (2) by inserting ``, under a loan repayment program awarded 
        a grant or contract under section 748(a)(2) of such Act'' after 
        ``section 338I of such Act''.
    (b) Effective Date.--The amendments made by this section shall 
apply to amounts received in taxable years beginning after the date of 
the enactment of this Act.
    (c) GAO Report.--The Comptroller General of the United States shall 
review and report to the appropriate committees of Congress on the 
participation of dental providers and faculty in areas and schools 
receiving funding from the Dental Faculty Development and Loan 
Repayment Program under section 748(a)(2) of the Public Health Service 
Act (42 U.S.C. 293k-2(a)(2)), including the extent to which such 
individuals remain full-time faculty teaching and practicing in dental 
clinics located in dental schools, hospitals, or community-based 
affiliated sites after receiving funding from the program.
                                 <all>
```
<PAGE>

                                                                    EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the quarterly report on Form 10-Q of Biopure Corporation
for the period ended January 31, 2004, I, Ronald F. Richards, Chief Financial
Officer, hereby certify, to the best of my knowledge, pursuant to 18 U.S.C.
1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

     1.   the Form 10-Q for the period ended January 31, 2004, fully complies
          with the requirements of section 13(a) or 15(d) of the Securities
          Exchange Act of 1934; and

     2.   the information contained in the Form 10-Q for the period ended
          January 31, 2004 fairly presents, in all material respects, the
          financial condition and results of operations of Biopure Corporation.

/s/ Ronald F. Richards
----------------------
Ronald F. Richards
Chief Financial Officer

March 15, 2004
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1040 Powered algesimeter. ( a ) *Identification.* A powered algesimeter is a device using electrical stimulation intended to determine a patient's sensitivity to pain after administration of an anesthetic agent.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 84 FR 71811, Dec. 30, 2019]
§ 884.1040 Viscometer for cervical mucus. ( a ) *Identification.* A viscometer for cervical mucus is a device that is intended to measure the relative viscoelasticity of cervical mucus collected from a female patient. Measurements of relative viscoelasticity are intended for use as an adjunct in the clinical evaluation of a female with chronic infertility, to determine the time of ovulation and the penetrability of cervical mucus to motile sperm.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 884.9.
[47 FR 14706, Apr. 6, 1982, as amended at 65 FR 2320, Jan. 14, 2000]
# C_2019239EN.01001501.xml

| 16.7.2019 | EN | Official Journal of the European Union | C 239/15 |
| --- | --- | --- | --- |

16.7.2019

EN

Official Journal of the European Union

C 239/15

---

Corrigendum to the Non-Binding Criteria for the application of Articles 290 and 291 of the Treaty on the Functioning of the European Union — 18 June 2019

(
  Official Journal of the European Union C 223 of 3 July 2019
  )

(2019/C 239/10)

On the cover, in the table of contents, and on page 1, in the heading:

for:

‘COUNCIL’,

read:

read:

‘EUROPEAN PARLIAMENT

COUNCIL

EUROPEAN COMMISSION’.

---
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

  PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

          Date of Report (Date of earliest event reported) May 29, 2003

                           EDGE PETROLEUM CORPORATION
               --------------------------------------------------
             (Exact name of registrant as specified in its charter)

          DELAWARE                    000-22149                 76-0511037
--------------------------------------------------------------------------------
(State or other jurisdiction         (Commission              (IRS Employer
     of incorporation)                 File No.)             Identification No.)

                   1301 Travis, Suite 2000, Houston, TX 77002
               --------------------------------------------------
               (Address of principal executive offices) (Zip Code)

        Registrant's telephone number, including area code (713) 654-8960

                                "NOT APPLICABLE"
               --------------------------------------------------
         (Former name or former address, if changed since last report.)


<PAGE>

Item 9. Regulation FD Disclosure.

      The following information is being furnished under Item 12.

      On May 29, 2003, Edge Petroleum Corporation issued a press release
announcing a merger with Miller Exploration Company. A copy of the press release
is attached hereto as Exhibit 99.1.

Item 7. Financial Statements and Exhibits

      (c) Exhibits.

      Exhibit 99.1
      Press release dated May 29, 2003.


<PAGE>

                                    Signature

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                         Edge Petroleum Corporation

May 29, 2003                             By: /s/ Michael G. Long
                                             ----------------------------------
                                                       Michael G. Long
                                               Senior Vice President and Chief
                                              Financial and Accounting Officer
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1310 Nuclear tomography system. ( a ) *Identification.* A nuclear tomography system is a device intended to detect nuclear radiation in the body and produce images of a specific cross-sectional plane of the body by blurring or eliminating detail from other planes. This generic type of devices may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.
( b ) *Classification.* Class II.
§ 516.31 Scope of MUMS-drug exclusive marketing rights. ( a ) After conditional approval or approval of an application for a MUMS-designated drug in the dosage form and for the intended use for which MUMS-drug designation has been granted, FDA will not conditionally approve or approve another application or abbreviated application for the same drug in the same dosage form for the same intended use before the expiration of 7 years after the date of conditional approval or approval as stated in the approval letter from FDA, except that such an application can be conditionally approved or approved sooner if, and at such time as, any of the following occurs: ( 1 ) FDA terminates the MUMS-drug designation and associated exclusive marketing rights under § 516.29; or
( 2 ) FDA withdraws the conditional approval or approval of the application for the drug for any reason; or
( 3 ) The sponsor with exclusive marketing rights provides written consent to FDA to conditionally approve or approve another application before the expiration of 7 years; or
( 4 ) The sponsor fails to assure a sufficient quantity of the drug in accordance with section 573 of the act and § 516.36.
( b ) If an application for a MUMS drug cannot be approved until the expiration of the period of exclusive marketing of a MUMS-designated drug, FDA will so notify the sponsor in writing.
§ 884.6140 Assisted reproduction micropipette fabrication instruments. ( a ) *Identification.* Assisted reproduction micropipette fabrication devices are instruments intended to pull, bevel, or forge a micropipette or needle for intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF) or other similar assisted reproduction procedures.
( b ) *Classification.* Class II (special controls) (design specifications, labeling requirements, and clinical testing).
I 

118TH CONGRESS 

2D SESSION H. R. 7911 

To amend title 13, United States Code, to prohibit the use of questions 

on citizenship, nationality, or immigration status in any decennial census, 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 9, 2024 

Ms. NORTON introduced the following bill; which was referred to the 

Committee on Oversight and Accountability 

A BILL 

To amend title 13, United States Code, to prohibit the use 

of questions on citizenship, nationality, or immigration 

status in any decennial census, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Ensuring Full Partici5 pation in the Census Act of 2024’’. 

6 SEC. 2. PROHIBITING CENSUS QUESTIONS ON CITIZENSHIP, 

7 NATIONALITY, OR IMMIGRATION STATUS. 

8 Section 141 of title 13, United States Code, is 

9 amended— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7911 IH

1 (1) by redesignating subsection (g) as sub2 section (h); and 

3 (2) by inserting after subsection (f) the fol4 lowing: 

5 ‘‘(g)(1) Except as provided in paragraph (2), a ques6 tionnaire or survey used to carry out, or in connection 

7 with, any decennial census of population may not include 

8 any question regarding citizenship, nationality, or immi9 gration status of the respondent, any family member of 

10 the respondent, or any individual living in the respondent’s 

11 household. 

12 ‘‘(2) Paragraph (1) shall not apply to the survey, con13 ducted by the Secretary, commonly referred to as the 

14 ‘American Community Survey’.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
JRN-28-2010 11:26 BOBBY JINDAL GOVERNOR P.02 HAROLD LEGGETT, PH.D. SECRETI\RY


### JAN 

## 06 201D 

## ~tate 

# of 

# 1Loul£itana DEPARTMENT OFENVIRONMENTAL QUALITY 

### ENVIRONMENTALASSESSMENT Mr, Charles Faultry AssociateDirector, Superfund Remedial Branch US Envirorunental ProtectionAgency, Region 6 1445 Ross Avenue, Suite 1200 **Dallas~** TX 75202-2733 Re.: Concurrence to Fina.lize the Final Close Out Report Ruston Foundry Superfund Site; AI Number (12443) 1010 Bogan Street, Alexandria, Rapides Parish, LA 

### Dew· 

### Mr. Faultry: The LouisianaDepartment ofEnvironmental QualityIRemediation Services 

### Division (LDEQ/RSD) is in receipt ofthe Final Close Out Report dated January 2010, Thank you for prOViding this information. Based upon our review ofyour submittal, 

### LDEQ/RSD concurs with the lrlformation found inthe referenced document. As areSUlt) the Department supports the U. S. Envirorunental Protection Agency's (EPA) position 

### to finalize the closure 

### proceduresfor this site. You may contact Wanda Ballou at (225) 219-3223 with any questions. Please continue to address any future correspondence with the AI number to: Thomas F, Harris, Administrator; Remediation Senrices Division; P.O, Box 4314; Baton Rouge, LA 70821·4314. 'rhankyou for your support and assistance in addressing this site. Sincerely>

**l~homas** F. Harris, Administrator Remediation Services Division c; Imaging Operations - lAS

POSt Of6ceBox 4314- Baton Rouge, Louisiana 70821-4314 • Pl uru"v"'\,..n **'t)"i~j~ ""'~.O'()V**  )..219..3236 • Fax 225-21-9-3239 TOTAL P.02JAN-28-2010 11:26 P.01 

# FAXTRANSJvfITTAL Office ofEnvil"onlnental Assessment 

## P. O. Box 4314 Baton Rouge, 

## LA 70821-4314 Phone: (225) 219-3236



## Fax: (225) 219-3239 

# DEQ LOUtStANA Date 

# !ItAf

# j;0 Time: 

### ---<1,--,O,---.,-,'0,-,O ....

Owlh4--_ 

### # Pages 

### to Follow: 

# ~/

__ TO: 

# j(aml;q **ih3r(~s'** !'aH;U'4 Company' 

# /lSEPIi REGIONAL OFFICES'

_......:Acadiana - 

### Lafayette



### . fax: (337) 262-5593

__,Bayou Lafourche - Lockport 

### fax: (504) 532-9945

__Capital - 

### Baton Rouge fax: (225) 765-0866

__,Kisatchie . 

### Alexandria 

### fax: (318) 487-5927 Northeast - 

### Monroe 

### --'fax. (318) 362-5448 _---'Northwest - Shreveport 

### fax: (318) 676-7573 **_~Southeast** - 

### New Orleans 

### fax: (504)736-7702

__,Southwest - Lake Charles 

### fax. (337) 491-2682 ALL REGIONS Commentsllnstructiol1s: 

# p;()~ 

# ( ?(O<L, {)u! 

# fe /lor/- 

### C€hWranU

**~** "



### FROM: 

# ryl(;/lJa. 

# 13k!l P

### I4 Phone: 

## IDCC( Group/Section. 

# £50- 7
<TABLE> <S> <C>

<ARTICLE>     5
<LEGEND>  THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
  FROM THE CONSOLIDATED BALANCE SHEET AS OF JUNE 29, 1996 AND THE
  CONSOLIDATED STATEMENT OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 29,
  1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
  STATEMENTS.
<MULTIPLIER>  1,000
       
<S>                                    <C>
<PERIOD-TYPE>                          6-MOS
<FISCAL-YEAR-END>                      DEC-28-1996
<PERIOD-END>                           JUN-29-1996
<CASH>                                   66,496 
<SECURITIES>                              6,500
<RECEIVABLES>                            67,381
<ALLOWANCES>                              5,646
<INVENTORY>                              49,502
<CURRENT-ASSETS>                        205,751
<PP&E>                                   96,698
<DEPRECIATION>                           53,346 
<TOTAL-ASSETS>                          261,126
<CURRENT-LIABILITIES>                    60,036
<BONDS>                                       0
<COMMON>                                     22
<PREFERRED-MANDATORY>                         0
<PREFERRED>                                   0
<OTHER-SE>                              197,280
<TOTAL-LIABILITY-AND-EQUITY>            261,126
<SALES>                                 184,282 
<TOTAL-REVENUES>                        184,282
<CGS>                                   133,919
<TOTAL-COSTS>                           133,919
<OTHER-EXPENSES>                              0
<LOSS-PROVISION>                          4,678
<INTEREST-EXPENSE>                          252
<INCOME-PRETAX>                          10,882
<INCOME-TAX>                              3,917
<INCOME-CONTINUING>                       6,965 
<DISCONTINUED>                                0
<EXTRAORDINARY>                               0
<CHANGES>                                     0
<NET-INCOME>                              6,965
<EPS-PRIMARY>                              0.32
<EPS-DILUTED>                              0.31  
        

</TABLE>
EXHIBIT 10.9
NOTICE OF TERMINATION OF CONSULTING AGREEMENT WITH FRANK PINIZZOTTO

FROM: Bill Forhan [mailto:bforhan@invictatravelgroup.com]
SENT: Saturday, March 08, 2003 5:48 PM
TO: Frank Pinizzotto (hittpr@aol.com)
CC: david Scott (dscott@invictatravelgroup.com); Jackson Morris
(jmorris8@tampabay.rr.com)
SUBJECT: Termination of Agreement

March 8, 2003

Regarding:  FRANK PINIZZOTTO MANAGEMENT CONSULTING AGREEMENT
            ------------------------------------------------

Dear Frank:

Invicta Group Inc. is canceling the Management Consulting Agreement entered into
January 8, 2003.

We regret this action, but the lack of communication and lack of performance has
resulted in termination.

Best of Luck,

William Forhan


Bill Forhan
CEO
Invicta Group Inc.
9553 Harding Ave. Suite 301
Miami Beach, Fl.33154
fax: 954 785 1508
cell: 954 684 8288
|                                      |
|--------------------------------------|
|                                      |  |
| Deutsche Bank Trust Company Americas | BNY Mellon Trust of Delaware |
| As Indenture Trustee                 | As Owner Trustee |
| Attn:  Michelle H.Y. Voon  | Attn:  Kristine Gullo |
| 100 Plaza One 6th Floor         | 301 Bellevue Parkway 3rd Floor |
| Jersey City, NY 07311                | Wilimingtom, DE  19809 |

|                                                 |
|-------------------------------------------------|
|                                                 |  |
| The Bank of New York Mellon Trust Company, N.A. | Ally Auto Assets LLC |
| Attn:  Robert Castle                  | Ally Financial Inc. |
| 2 North LaSalle Street, Suite 1020              | 200 Renaissance Center |
| Chicago, IL  60602                    | 10th Floor, MC 482-B10-A68 |
|                                            | Detroit, MI |

|        |
|--------|
|        |  |
| Re:    | Ally Auto Receivables Trust 2015-1 |
|   | Annual Statement as to Compliance |

|    |
|----|
|    |  |
| a. | A review of the activities of the Servicer during the period of July 22, 2015 through December 31, 2015, and of its performance under the Servicing Agreement has been under his supervision, and |

|    |
|----|
|    |  |
| b. | To the best of his knowledge, based on such review, the Servicer has fulfilled all of its obligations under the Servicing Agreement throughout such period. |

|        |
|--------|
|        |  |  |
|   | Very truly yours, |
|   |   |
|   | /s/ David J. DeBrunner |   |
|   | David J. DeBrunner |
|   | Vice President, Controller and Chief Accounting Officer |
|   | Ally Financial Inc. |
#### § 54.3 Scope.

The requirements in this part apply to any applicant who submits a marketing application for a human drug, biological product, or device and who submits covered clinical studies. The applicant is responsible for making the appropriate certification or disclosure statement where the applicant either contracted with one or more clinical investigators to conduct the studies or submitted studies conducted by others not under contract to the applicant.
# C_2014235EN.01002001.xml

| 21.7.2014 | EN | Official Journal of the European Union | C 235/20 |
| --- | --- | --- | --- |

21.7.2014

EN

Official Journal of the European Union

C 235/20

---

Action brought on 28 March 2014 — LR Health & Beauty Systems/OHIM — Robert McBride (LR nova pure.)

(Case T-202/14)

2014/C 235/27

Language in which the application was lodged: English

Parties

Parties

Applicant: LR Health & Beauty Systems GmbH (Ahlen, Germany) (represented by: N. Weber and L. Thiel, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Robert McBride Ltd (Manchester, United Kingdom)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 22 January 2014 in case R 272/2013-2; |
| --- | --- |

—

Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 22 January 2014 in case R 272/2013-2;

| — | Order the defendant and, if appropriate, the other party to the proceedings to pay the costs. |
| --- | --- |

—

Order the defendant and, if appropriate, the other party to the proceedings to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: The applicant

Applicant for a Community trade mark:

Community trade mark concerned: The figurative mark containing the word elements ‘LR nova pure.’ for goods in Class 3 — Community trade mark application No 9 8 51  361

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: The other party to the proceedings before the Board of Appeal

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: International trade mark registration of the word mark NOVA

Mark or sign cited in opposition:

Decision of the Opposition Division: Upheld the opposition

Decision of the Opposition Division:

Decision of the Board of Appeal: Dismissed the appeal

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) of Regulation No 207/2009

Pleas in law:

---
**Exhibit32.2**

 

**CERTIFICATIONOF PERIODIC REPORT**

 

I, Cameron B. Waite, Executive Vice President and Chief FinancialOfficer of Penn Treaty American Corporation, certify, pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.Section 1350, that:

 

(1) the Quarterly Report on Form 10-Q of the Company for the quarterlyperiod ended September 30, 2003 (the “Report’’) fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Act of1934 (15 U.S.C. 78m or 78o(d)); and

 

(2) the information contained in the Report fairly presents, in allmaterial respects, the financial condition and results of operations of theCompany.

 
| Date:  November 11,  2003 | /s/ Cameron B. Waite                          |   |
|------------------------------------------|-----------------------------------------------|--------|
|                                     |                                          |
|                                     | Cameron B. Waite                              |
|                                     | Exec. Vice President Chief  Financial Officer |

 

1

----
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2750 Impedance phlebograph. ( a ) *Identification.* An impedance phlebograph is a device used to provide a visual display of the venous pulse or drainage by measuring electrical impedance changes in a region of the body.
( b ) *Classification.* Class II (performance standards).